Telehealth Psych

LyfeUnit / www.lyfeunit.com

FDA issued a warning letter to LyfeUnit (www.lyfeunit.com) on June 23, 2026, for selling unapproved and misbranded ketamine drug products to U.S. consumers via the internet without a valid FDA-approved drug application and without requiring a prescription. The site marketed injectable ketamine vials (Rotexmedica Ketamine 500mg/10ml) with claims referencing mental health treatments and anesthetic indications, in violation of sections 301, 502, 503, and 505 of the FD&C Act. FDA warned that failure to comply may result in seizure and injunction, and demanded a written corrective response within 15 business days.

WPATH, FTC v.

The FTC, joined by Alaska, Iowa, Nebraska, and Texas, filed a lawsuit against the World Professional Association for Transgender Health (WPATH), alleging the organization provided medical providers with the means to make false and unsubstantiated claims to parents in order to sell pediatric medical transition services. The complaint centers on WPATH's role in enabling downstream marketing of these services through claims the FTC characterizes as unsupported by adequate scientific evidence. This is a multi-state enforcement action seeking to hold a professional standards body liable for facilitating deceptive health claims. No specific penalty amount or corrective deadline is stated in the available document text.

Evoke Wellness, LLC., FTC v.

The FTC sued Florida-based Evoke Wellness, LLC, Evoke Health Care Management, and their officers Jonathan Mosley and James Hull in January 2025 for using deceptive Google search ads and telemarketing to impersonate other substance use disorder treatment providers. The defendants misled consumers seeking addiction treatment by masquerading as competing or well-known providers. A settlement was reached in June 2025 in which the defendants were barred from the deceptive conduct and agreed to pay a $1.9 million civil penalty.

Monument, Inc., U.S. v.

The FTC took action against Monument, Inc., an online alcohol addiction treatment service, for allegedly disclosing users' sensitive personal health data — including information about their alcohol use and treatment — to third-party advertising platforms such as Meta and Google without consumer consent. This occurred despite Monument's promises to keep such information confidential. The case represents a critical enforcement action targeting unauthorized sharing of health data for advertising purposes.

Cerebral, Inc. and Kyle Robertson, U.S. v.

Cerebral, Inc. and its CEO Kyle Robertson agreed to an FTC consent order resolving charges that the telehealth company failed to adequately secure and protect sensitive consumer health data. The order restricts how Cerebral may use or disclose sensitive consumer data and requires the company to provide consumers with a simple cancellation mechanism. The FTC's action targeted data security and privacy practices rather than specific marketing claims. This is a critical enforcement action given the consent order and mandatory operational restrictions imposed.

Simple Health Plans LLC

The FTC filed a federal court complaint against Simple Health Plans LLC, Steven J. Dorfman, and related entities in October 2018, alleging that defendants deceived consumers into believing they were purchasing comprehensive health insurance covering preexisting conditions, prescription drugs, specialist care, hospital services, surgeries, and lab testing. An amended complaint was filed in November 2019 adding Candida Girouard as a defendant. The case centers on fraudulent misrepresentation of health plan coverage rather than specific therapeutic marketing claims. This is a critical enforcement action involving federal court litigation.

GoodRx Holdings, Inc.

The FTC took its first-ever enforcement action under the Health Breach Notification Rule against GoodRx Holdings, Inc., a telehealth and prescription drug discount provider. GoodRx failed to notify consumers, the FTC, and media of its unauthorized disclosures of consumers' personal health information to third parties including Facebook and Google. This action marks a landmark use of the Health Breach Notification Rule in the telehealth space. The enforcement resulted in a consent order requiring GoodRx to remediate its data-sharing practices and pay civil penalties.

Vision Path, Inc., d/b/a Hubble Contacts, U.S. v.

Vision Path, Inc. (d/b/a Hubble Contacts), an online direct-to-consumer contact lens seller, settled FTC charges in January 2022 for violating the Contact Lens Rule by failing to obtain and properly verify prescriptions and substituting Hubble lenses for those actually prescribed. The FTC also alleged the company violated the FTC Act by failing to disclose that many consumer reviews were written by compensated reviewers, including at least one company executive. The settlement required Vision Path to pay $3.5 million in penalties and consumer redress.

Lifewatch Inc.

Lifewatch Inc., Evan Sirlin, and Mitchel May were found liable for conducting over one billion illegal robocalls targeting primarily elderly consumers to pitch supposedly 'free' medical alert systems. The FTC, acting jointly with the Florida Attorney General's Office, alleged the defendants misrepresented the terms of their medical alert product sales since 2012. A court order permanently bans the Lifewatch defendants from telemarketing and prohibits misrepresentation of product or service terms. A financial judgment of $25.3 million was imposed against Lifewatch and Sirlin.

Flo Health, Inc.

Flo Health, Inc., a period and fertility tracking app, settled FTC allegations that it shared users' sensitive health information — including menstrual and pregnancy data — with third-party analytics providers such as Facebook and Google, despite promising users that such information would remain private. The FTC found this constituted an unfair or deceptive practice under Section 5 of the FTC Act. The consent order requires Flo Health to notify affected users and instruct third parties to delete the improperly shared data.

Rennert, Sandra L., et al.

The FTC brought action against Sandra L. Rennert, Philip Rennert, and associated entities including Focus Medical Group, World Wide RX, World Wide Medicine, and Doctors A.S.A.P. for deceptive health claims and marketing practices conducted online. The case involved consumer protection violations related to advertising, marketing, and health claims. The matter resulted in a consent order, indicating the FTC found sufficient cause to require formal corrective action from the respondents.